156 related articles for article (PubMed ID: 31125092)
1. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment.
Ferrari S; Butler PW; Kendler DL; Miller PD; Roux C; Wang AT; Huang S; Wagman RB; Lewiecki EM
J Clin Endocrinol Metab; 2019 Aug; 104(8):3450-3461. PubMed ID: 31125092
[TBL] [Abstract][Full Text] [Related]
2. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
3. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
4. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
5. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
6. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
Bilezikian JP; Lin CJF; Brown JP; Wang AT; Yin X; Ebeling PR; Fahrleitner-Pammer A; Franek E; Gilchrist N; Miller PD; Simon JA; Valter I; Zerbini CAF; Libanati C; Chines A
Osteoporos Int; 2019 Sep; 30(9):1855-1864. PubMed ID: 31201481
[TBL] [Abstract][Full Text] [Related]
7. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.
Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD
J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870
[TBL] [Abstract][Full Text] [Related]
8. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
9. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.
Bone HG; Chapurlat R; Brandi ML; Brown JP; Czerwinski E; Krieg MA; Mellström D; Radominski SC; Reginster JY; Resch H; Ivorra JA; Roux C; Vittinghoff E; Daizadeh NS; Wang A; Bradley MN; Franchimont N; Geller ML; Wagman RB; Cummings SR; Papapoulos S
J Clin Endocrinol Metab; 2013 Nov; 98(11):4483-92. PubMed ID: 23979955
[TBL] [Abstract][Full Text] [Related]
10. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
Kendler DL; Chines A; Brandi ML; Papapoulos S; Lewiecki EM; Reginster JY; Muñoz Torres M; Wang A; Bone HG
Osteoporos Int; 2019 Jan; 30(1):71-78. PubMed ID: 30244369
[TBL] [Abstract][Full Text] [Related]
11. Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension.
Ferrari S; Eastell R; Napoli N; Schwartz A; Hofbauer LC; Chines A; Wang A; Pannacciulli N; Cummings SR
Bone; 2020 May; 134():115268. PubMed ID: 32058020
[TBL] [Abstract][Full Text] [Related]
12. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.
Adami S; Libanati C; Boonen S; Cummings SR; Ho PR; Wang A; Siris E; Lane J; ; Adachi JD; Bhandari M; de Gregorio L; Gilchrist N; Lyritis G; Möller G; Palacios S; Pavelka K; Heinrich R; Roux C; Uebelhart D
J Bone Joint Surg Am; 2012 Dec; 94(23):2113-9. PubMed ID: 23097066
[TBL] [Abstract][Full Text] [Related]
13. Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
Dempster DW; Brown JP; Fahrleitner-Pammer A; Kendler D; Rizzo S; Valter I; Wagman RB; Yin X; Yue SV; Boivin G
J Clin Endocrinol Metab; 2018 Jul; 103(7):2498-2509. PubMed ID: 29672714
[TBL] [Abstract][Full Text] [Related]
14. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT).
Nakamura T; Matsumoto T; Sugimoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Shiraki M; Fukunaga M
J Clin Endocrinol Metab; 2014 Jul; 99(7):2599-607. PubMed ID: 24646104
[TBL] [Abstract][Full Text] [Related]
15. Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed.
Ferrari S; Lewiecki EM; Butler PW; Kendler DL; Napoli N; Huang S; Crittenden DB; Pannacciulli N; Siris E; Binkley N
Bone; 2020 May; 134():115287. PubMed ID: 32092479
[TBL] [Abstract][Full Text] [Related]
16. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
[TBL] [Abstract][Full Text] [Related]
17. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
18. Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
Adachi JD; Bone HG; Daizadeh NS; Dakin P; Papapoulos S; Hadji P; Recknor C; Bolognese MA; Wang A; Lin CJF; Wagman RB; Ferrari S
BMC Musculoskelet Disord; 2017 Apr; 18(1):174. PubMed ID: 28449657
[TBL] [Abstract][Full Text] [Related]
19. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
20. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
Watts NB; Roux C; Modlin JF; Brown JP; Daniels A; Jackson S; Smith S; Zack DJ; Zhou L; Grauer A; Ferrari S
Osteoporos Int; 2012 Jan; 23(1):327-37. PubMed ID: 21892677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
